Healthcare Industry News:  Calypso Medical Technologies 

Devices Oncology

 News Release - November 2, 2009

Calypso Medical Studies Show Potential for Improving Radiotherapy Treatment Accuracy

More than 30 Calypso-related scientific studies presented at ASTRO

SEATTLE & CHICAGO--(HSMN NewsFeed)--Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced Calypso’s real-time tracking technology is included in 36 scientific presentations and posters at the 51st Annual Meeting of the American Society for Therapeutic Radiation Oncology (ASTRO), now underway at McCormick Place in Chicago. These studies highlight the potential applications of the technology and the benefits associated with real-time tracking of the prostate, for which the Calypso(R) System is currently commercially available.

The topics of prostate-related studies include prostate SBRT, prone prostate treatment, workflow efficiency, and dose escalation. Studies of investigational applications, such as high-velocity pancreatic and lung tumors, will also be presented. Calypso is exhibiting during this conference at booth 1231 and Calypso Systems will also be displayed in collaboration with Siemens Healthcare at booth 1829 and Varian Medical Systems at booth 2229.

According to the American Cancer Society, prostate cancer is the leading cancer in men in the United States with 192,000 new cases diagnosed each year. The prostate is also the most common target for radiation therapy in the body. Since the radiation beam is more precisely focused on the tumor target, Calypso’s technology allows clinicians to more tightly contour the radiation dose to the prostate and minimize unwanted dose to adjacent healthy tissues.

“Calypso allows us to track the position of the prostate during prolonged, high-dose SBRT treatments and provides the flexibility to stop the treatment if the prostate moves outside the intended field of radiation,” said Constantine Mantz, M.D., at 21st Century Oncology in Cape Coral, Florida. “Without Calypso, we are really just flying blind.”

In addition to prostate-related studies, data is being presented from an investigational study demonstrating the utility of the Calypso System in tracking tumor movement in the canine lung.

According to the Centers for Disease Control and Prevention, more people die from lung cancer than any other cancer type. In 2005, the most recent year for which statistics are currently available, lung cancer accounted for more deaths than breast, prostate, and colon cancers combined. In that year, 196,687 people were diagnosed with lung cancer and 159,217 people died from the disease.

“The lung often undergoes dramatic movement and distortion during normal respiration, sighing, and coughing, making targeting an extremely complicated task to handle,” said Martin Mayse, M.D., an interventional pulmonologist at Barnes Jewish Hospital in St. Louis and an investigator on the study. “With the Calypso System, we will have real-time data that tells us exactly what is going on while the patient is breathing. We will not have to make assumptions anymore.”

“The research we have conducted clearly shows that the bronchoscopic insertion of an anchored transponder is not only safe, but also does not migrate,” said Parag Parikh, M.D., assistant professor of radiation oncology and biomedical engineering at Washington University in St. Louis. “This opens up the use of electromagnetic tracking for lung tumors.”

The Calypso System will be the topic of several scientific sessions, including an independent investigation conducted at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) in Heidelberg in which researchers demonstrated real-time multi-leaf collimator tracking, as well as a study conducted at Stanford University demonstrating Calypso-guided dynamic multi-leaf collimator (DMLC) target tracking with Intensity Modulated Arc Therapy (IMAT). Dose distributions to moving targets with DMLC tracking were superior to those without tracking.

“We continue to be encouraged with a growing body of research that suggests promise in areas of the body that have proved difficult to treat effectively,” said Eric R. Meier, president and chief executive officer of Calypso Medical. “The ability to monitor tumor motion and automatically adapt treatment may lead to improved treatment accuracy and delivery.”

Information about the oral presentations featuring Calypso technology referenced in this news release is listed below:
  • Long-term Interaction and Tissue Response of a Bronchoscopically Implanted, Anchored Electromagnetic Transponder in the Canine Lung, Mayse et al, Washington University, St. Louis
  • Real-time Tumor Position Monitoring and Dynamic Dose Adaptation: Geometrical and Dosimetric Accuracy of an Integrated Tracking System, Oelfke et al, DKFZ, Heidelberg, Germany
  • Electromagnetic-guided DMLC Tracking Enables Motion Management for Intensity Modulated Arc Therapy, Keall et al, Stanford University, Palo Alto, Calif.
Additional Calypso-related oral presentations include:
  • First Report of Real-time Tumor Tracking in the Treatment of Pancreatic Cancer Using the Calypso(R) System, Metz et al, University of Pennsylvania, Philadelphia, Pa.
  • Patient-reported Reduction in Acute GU and GI Side Effects for Prostate Cancer Patients Treated with 81Gy IMRT Using Reduced PTV Margins and Electromagnetic Tracking, Khan et al, 21st Century Oncology, Santa Monica, Calif.
Also highlighted as a work-in-progress will be Calypso’s Dynamic Edge™ Gating Technology* that will utilize Calypso’s real-time target position information to enable and disable the treatment beam in response to motion of the prostate. The treatment beam can be automatically held when the target position goes outside the motion thresholds and automatically re-enabled when the target is within the motion thresholds.

“Dynamic Edge Gating Technology is the next step in utilizing the Calypso System to facilitate precision treatment delivery approaches. By automatically enabling and disabling the beam in response to target motion, we can further enhance highly accurate treatment for organs which invariably move during treatment,” said Ed Vertaschitsch, senior vice president, operations of Calypso Medical.

Also known as GPS for the Body(R), Calypso’s proprietary technology utilizes miniature implanted Beacon(R) transponders to provide precise, continuous information on the location of the tumor during external beam radiation therapy. Any movement by the patient, including internal movement of the tumor, may cause the radiation to miss its intended target and hit adjacent healthy tissue. In contrast to other tumor targeting solutions, the Calypso System provides continuous tumor position information, objectively and without ionizing radiation, thereby enabling an increase in the radiation delivered to the tumor while reducing radiation misapplied to normal tissue.

About Calypso Medical

Calypso Medical Technologies, Inc. is a Seattle-based, privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon electromagnetic transponders) to continuously, accurately and objectively track the location of tumors for improved accuracy and management of radiation therapy delivery. The technology is designed for body-wide cancers commonly treated with radiation therapy. The products are FDA 510(k) cleared for use in the prostate and post-operative prostatic bed. The Company has strategic relationships with Varian Medical Systems, Siemens Healthcare, Elekta Corporation and Philips Medical. Additional information can be found at http://www.calypsomedical.com.

* This technology is a concept device under development and not available for sale.


Source: Calypso Medical Technologies

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.